Thryv Therapeutics
Laval
About Thryv Therapeutics
Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventricular arrhythmias. Click below to learn more about our programs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $40.4M
- Last round: Series Unknown (Sep 2025)
- Website: thryvtrx.com
- Phone: +1 514 973 0915
Industries & Categories
Biotechnology, Precision Medicine, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/thryv-therapeutics-59164 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.